<DOC>
	<DOCNO>NCT00920439</DOCNO>
	<brief_summary>The study evaluate safety reactogenicity PoliorixTM give single booster dose Chinese child 18-24 month age .</brief_summary>
	<brief_title>Safety Reactogenicity GlaxoSmithKline ( GSK ) Biologicals ' IPV Vaccine ( PoliorixTM ) Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female toddler , include , 18 24 month age time booster vaccination . Subjects receive three dos OPV primary vaccination first year life per Chinese recommendation . Subjects investigator believe parents/ guardian comply requirement protocol enrol study . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster vaccination Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period , exception DTP and/or Hib vaccine ( ) . Administration immunoglobulins and/or blood product within three month precede booster vaccination , plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Previous booster vaccination poliomyelitis since end primary vaccination series . History poliomyelitis disease . History seizures progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . The following condition temporary selflimiting subject may vaccinate condition resolve exclusion criterion meet : • Current febrile illness axillary temperature &gt; 37.0 ºC moderate severe illness within 24 hour study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Poliomyelitis Vaccines</keyword>
	<keyword>IPV</keyword>
</DOC>